ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
82.765
0.00%
US Dollar vs AUD
1.514
0.00%
Bitcoin
63,891.23
0.00%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Harpoon Therapeutics Inc (HARP)

  7. Harpoon Therapeutics Inc (HARP) News

HARP Harpoon Therapeutics Inc

23.01
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Harpoon Therapeutics Inc HARP NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 23.01 10:00:00
Open Price Low Price High Price Close Price Previous Close
23.01 23.01
more quote information »

Recent News

Date Time Source Heading
12/3/202408:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/3/202400:55EDGAR2Form POS AM - Post-Effective amendments for registration..
12/3/202400:46EDGAR2Form S-8 POS - Securities to be offered to employees in..
11/3/202423:47EDGAR2Form 8-K - Current report
09/3/202408:04EDGAR2Form 8-K - Current report
28/2/202423:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/2/202423:34EDGAR2Form 8-K - Current report
23/2/202400:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/2/202400:31EDGAR2Form 8-K - Current report
08/2/202423:00EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
07/2/202408:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202408:52EDGAR2Form PREM14A - Preliminary proxy statements relating to..
30/1/202408:28EDGAR2Form 8-K - Current report
11/1/202407:07PRNUSKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to..
09/1/202422:12IHMARKETNEWSWall Street Highlights: HPE and Juniper Networks in..
09/1/202409:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/1/202409:16EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/1/202400:04EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/1/202400:01EDGAR2Form 8-K - Current report
08/1/202423:30BWMerck to Acquire Harpoon Therapeutics, Further Diversifying..
06/1/202409:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
26/12/202323:30GLOBEHarpoon Therapeutics Strengthens Leadership Team
23/12/202308:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/12/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
19/12/202323:30GLOBEHarpoon Therapeutics Abstract for HPN328 Accepted for Rapid..
12/12/202312:15GLOBEHarpoon Therapeutics Presents HPN217 Phase 1 Clinical Data..
09/12/202308:08EDGAR2Form S-3 - Registration statement under Securities Act of..
29/11/202308:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202308:14EDGAR2Form 8-K - Current report
25/11/202306:06EDGAR2Form 8-K - Current report
25/11/202306:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/11/202308:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202308:11EDGAR2Form 8-K - Current report
10/11/202308:01GLOBEHarpoon Therapeutics Reports Third Quarter 2023 Financial..
04/11/202307:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
03/11/202300:15GLOBEHarpoon Therapeutics Abstract for HPN217 Accepted for..
27/10/202308:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
23/10/202323:00EDGAR2Form 8-K - Current report
23/10/202322:17GLOBEHarpoon Therapeutics Announces Up to $150 Million Private..
22/10/202302:31GLOBEHarpoon Therapeutics Announces Updated Interim Tolerability..
17/10/202307:05GLOBEHarpoon Therapeutics to Host Webcast Reviewing HPN328..
10/10/202307:17GLOBEHarpoon Therapeutics to Present Interim Tolerability and..
03/10/202308:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202317:00GLOBEHarpoon Therapeutics Presents HPN217 Interim Phase 1 Data at..
15/9/202321:15GLOBEHarpoon Therapeutics Announces First Patients with Small..
14/9/202307:12DJNHarpoon Shares Drop 7.3% as AbbVie Declines License Option
14/9/202306:55DJNHarpoon Therapeutics Says AbbVie Declines to Exercise..
14/9/202306:15EDGAR2Form 8-K - Current report
14/9/202306:05GLOBEHarpoon Therapeutics Provides an Update on the HPN217..
06/9/202321:30GLOBEHarpoon Therapeutics Abstract for HPN217 Accepted for Poster..

Your Recent History

NASDAQ
HARP
Harpoon Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved